98%
921
2 minutes
20
Nutrient profiling systems (NPS) aim to discriminate the healthfulness of foods for front-of-package labelling, warning labels, taxation, company ratings and more. Existing NPS often assess relatively few nutrients and ingredients, use inconsistent criteria across food categories and have not incorporated the newest science. Here, we developed and validated an NPS, the Food Compass, to incorporate a broader range of food characteristics, attributes and uniform scoring principles. We scored 54 attributes across 9 health-relevant domains: nutrient ratios, vitamins, minerals, food ingredients, additives, processing, specific lipids, fibre and protein, and phytochemicals. The domain scores were summed into a final Food Compass Score (FCS) ranging from 1 (least healthy) to 100 (most healthy) for all foods and beverages. Content validity was confirmed by assessing nutrients, food ingredients and other characteristics of public health concern; face validity was confirmed by assessing the FCS for 8,032 foods and beverages reported in NHANES/FNDDS 2015-16; and convergent and discriminant validity was confirmed from comparisons with the NOVA food processing classification, the Health Star Rating and the Nutri-Score. The FCS differentiated food categories and food items well, with mean ± s.d. ranging from 17.1 ± 17.2 for savoury snacks and sweet desserts to 81.6 ± 16.0 for legumes, nuts and seeds. In many food categories, the FCS provided important discrimination of specific foods and beverages as compared with NOVA, the Health Star Rating or the Nutri-Score. On the basis of demonstrated content, convergent and discriminant validity, the Food Compass provides an NPS scoring a broader range of attributes and domains than previous systems with uniform and transparent principles. This publicly available tool will help guide consumer choice, research, food policy, industry reformulations and mission-focused investment decisions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/s43016-021-00381-y | DOI Listing |
CNS Drugs
August 2025
Supernus Pharmaceuticals, Inc., 9715 Key West Avenue, Rockville, MD, 20850, USA.
Background And Objective: Viloxazine ER (extended-release capsules; Qelbree) is a nonstimulant medication that has been approved by the United States Food and Drug Administration (FDA) for treatment of pediatric and adult attention-deficit/hyperactivity disorder (ADHD). This phase 3, open-label extension (OLE) trial evaluated the long-term safety and efficacy of viloxazine ER in children and adolescents with ADHD.
Methods: Participants completing the phase 2 or one of the four phase 3 double-blind, placebo-controlled clinical trials were eligible for the OLE trial.
Microbiol Res
August 2025
Natural Resource Management and Sustainability Program, School of Bioresources and Technology, King Mongkut's University of Technology Thonburi, Bangkuntien, Bangkok 10150, Thailand; LigniTech-Lignin Technology Research Group, School of Bioresources and Technology, King Mongkut's University of Techn
Mycovirus infections significantly impact fungal virulence and physiology, inducing either hypovirulence or hypervirulence. This study investigated the hypovirulent effects of Colletotrichum gloeosporioides RNA virus 1 (CgRV1-Ssa-44.1) infection on Colletotrichum gloeosporioides using multi-omics approaches.
View Article and Find Full Text PDFJ Immunother Cancer
July 2025
Oncology Global Clinical Development, GSK, Baar, Switzerland.
Immune checkpoint inhibitors targeting negative regulatory checkpoints including programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 have produced significant improvements in progression-free survival (PFS) and overall survival in multiple solid tumors. Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor that is highly expressed by exhausted T cells. Dual blockade of LAG-3 and PD-1 with monoclonal antibodies relatlimab and nivolumab has improved PFS in advanced melanoma, leading to Food and Drug Administration approval for this indication.
View Article and Find Full Text PDFJAMIA Open
August 2025
Parkland Center for Clinical Innovation (PCCI), Dallas, TX 75247, United States.
Objectives: To determine whether a novel digital tool, the Community Vulnerability Compass (CVC), built using large datasets, can accurately measure neighborhood- and individual-level social determinants of health (SDOH) at scale. Existing SDOH indexes fall short of this dual requirement.
Materials And Methods: : A cross-sectional study by Parkland Health (Parkland) and Parkland Center for Clinical Innovation (PCCI) to design, build, deploy, and validate CVC in Dallas County/across Texas (2018-2024).